PE20251601A1 - Inhibidores de kif18a y usos de estos - Google Patents
Inhibidores de kif18a y usos de estosInfo
- Publication number
- PE20251601A1 PE20251601A1 PE2025000401A PE2025000401A PE20251601A1 PE 20251601 A1 PE20251601 A1 PE 20251601A1 PE 2025000401 A PE2025000401 A PE 2025000401A PE 2025000401 A PE2025000401 A PE 2025000401A PE 20251601 A1 PE20251601 A1 PE 20251601A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halo
- kif18a
- membered monocyclic
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan compuestos de Formula (I) o sus sales farmaceuticamente aceptables, que son utiles para la inhibicion de KIF18A y en el tratamiento de una variedad de afecciones o enfermedades mediadas por KIF18A, como el cancer. Se trata de un compuesto representado por la Formula (I) o una sal farmaceuticamente aceptable de estos, donde: X1 y X2 son independientemente CR5 o N, y X3 es CR4 o N; el anillo A es fenilo, heteroarilo de 6 miembros, heteroarilo 6,5-biciclico o heterociclilo monociclico o biciclico de 4 a 10 miembros; Z es -NHC(O)- o -C(O)NH-, donde - representa la union al anillo A; o es un numero entero de 0 a 3; R1 es alquilo C1-6, cicloalquilo C3-6, heterociclilo monociclico de 3 a 6 miembros, entre otros; R2 es H, alquilo C1-6, halo, entre otros; R3 es cicloalquilo C3-6, fenilo o heterociclilo monociclico de 3 a 6 miembros, donde este ultimo esta opcionalmente sustituido con 1 o mas R3a; cada R3a se selecciona independientemente de halo, haloalquilo C1-6 o alquilo C1-6; entre otros; R4 es H, alquilo C1-6, haloalquilo C1-6 o halo; R5 es H, halo o alquilo C1-6.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263399003P | 2022-08-18 | 2022-08-18 | |
| US202363463617P | 2023-05-03 | 2023-05-03 | |
| PCT/US2023/030544 WO2024039829A1 (en) | 2022-08-18 | 2023-08-18 | Inhibitors of kif18a and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20251601A1 true PE20251601A1 (es) | 2025-06-16 |
Family
ID=88068723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2025000401A PE20251601A1 (es) | 2022-08-18 | 2023-08-18 | Inhibidores de kif18a y usos de estos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12391709B2 (es) |
| EP (1) | EP4572855A1 (es) |
| JP (1) | JP2025529821A (es) |
| KR (1) | KR20250078442A (es) |
| CN (1) | CN120187733A (es) |
| AU (1) | AU2023324826A1 (es) |
| CA (1) | CA3264917A1 (es) |
| CL (1) | CL2025000445A1 (es) |
| CO (1) | CO2025003263A2 (es) |
| CR (1) | CR20250087A (es) |
| MX (1) | MX2025001982A (es) |
| PE (1) | PE20251601A1 (es) |
| TW (1) | TW202416973A (es) |
| WO (1) | WO2024039829A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| PE20251601A1 (es) | 2022-08-18 | 2025-06-16 | Accent Therapeutics Inc | Inhibidores de kif18a y usos de estos |
| CN121100117A (zh) * | 2023-05-16 | 2025-12-09 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物、其制备方法和其在医药上的应用 |
| WO2025036479A1 (zh) * | 2023-08-16 | 2025-02-20 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| CN119504636A (zh) * | 2024-11-25 | 2025-02-25 | 上海筛杰生物医药有限公司 | 一种2-（4-氟苯基）-6-硝基-4-（2,2,2-三氟乙氧基）-1,2-苯并噻唑-3-酮的制备方法及其中间体和应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2997190T3 (en) * | 2018-12-20 | 2025-02-14 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors |
| IL283639B2 (en) * | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| EP3898616B1 (en) * | 2018-12-20 | 2024-10-02 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| US12459932B2 (en) * | 2018-12-20 | 2025-11-04 | Amgen Inc. | KIF18A inhibitors |
| EP4007753B1 (en) * | 2019-08-02 | 2025-09-24 | Amgen Inc. | Kif18a inhibitors |
| CA3147276A1 (en) * | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CA3146693A1 (en) * | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| KR20230011932A (ko) | 2020-04-14 | 2023-01-25 | 암젠 인크 | 신생물 질환의 치료를 위한 kif18a 저해제 |
| WO2021231413A1 (en) | 2020-05-11 | 2021-11-18 | University Of Vermont | A treatment approach involving kif18a inhibition for chromosomally unstable tumors |
| EP4361142A4 (en) | 2021-06-25 | 2025-07-09 | Hangzhou Innogate Pharma Co Ltd | COMPOUND FOR USE AS A KIF18A INHIBITOR |
| TW202321213A (zh) | 2021-07-21 | 2023-06-01 | 美商安進公司 | Ｋｉｆ１８ａ抑制劑化合物之鹽和固態形式 |
| MX2024002391A (es) | 2021-08-26 | 2024-06-03 | Volastra Therapeutics Inc | Inhibidores de indolina de kif18a. |
| CN115772159A (zh) | 2021-09-06 | 2023-03-10 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| CN115785068A (zh) | 2021-09-10 | 2023-03-14 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| CN118076586A (zh) | 2021-09-16 | 2024-05-24 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| WO2023049209A1 (en) | 2021-09-22 | 2023-03-30 | Volastra Therapeutics, Inc. | Systems and methods for evaluation of mitotic events using machine-learning |
| AU2022389558A1 (en) | 2021-11-19 | 2024-05-23 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Kif18a inhibitor |
| CA3248925A1 (en) | 2022-01-26 | 2023-08-03 | Amgen Inc. | SYNTHESIS OF A KIF18A INHIBITOR |
| CN118613478A (zh) | 2022-03-17 | 2024-09-06 | 微境生物医药科技(上海)有限公司 | Kif18a抑制剂 |
| CN116903605A (zh) | 2022-04-15 | 2023-10-20 | 武汉人福创新药物研发中心有限公司 | 一种kif18a抑制剂及其用途 |
| CN116925065A (zh) | 2022-04-22 | 2023-10-24 | 武汉人福创新药物研发中心有限公司 | 抑制kif18a的化合物及用途 |
| AU2023261964A1 (en) | 2022-04-28 | 2024-11-07 | Volastra Therapeutics, Inc. | Compounds for inhibiting kif18a |
| WO2023212714A1 (en) | 2022-04-29 | 2023-11-02 | Amgen Inc. | Kif18a inhibition for treatment of cancer |
| WO2023217233A1 (zh) | 2022-05-13 | 2023-11-16 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| CN116789637B (zh) | 2022-05-13 | 2024-08-02 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| CN117069694A (zh) | 2022-05-17 | 2023-11-17 | 武汉人福创新药物研发中心有限公司 | Kif18a的抑制剂及其用途 |
| KR20250027560A (ko) | 2022-06-30 | 2025-02-26 | 쑤저우 젠하우스 바이오 컴퍼니 리미티드 | 질소 함유 화합물 및 이의 용도 |
| CN117466899A (zh) | 2022-07-29 | 2024-01-30 | 武汉人福创新药物研发中心有限公司 | Kif18a抑制剂及用途 |
| CN117510463A (zh) | 2022-08-05 | 2024-02-06 | 长春金赛药业有限责任公司 | Kif18a抑制剂化合物、药物组合物及其制备方法和应用 |
| CN119522223A (zh) | 2022-08-11 | 2025-02-25 | 山东轩竹医药科技有限公司 | Kif18a抑制剂及其用途 |
| PE20251601A1 (es) | 2022-08-18 | 2025-06-16 | Accent Therapeutics Inc | Inhibidores de kif18a y usos de estos |
| KR20250044780A (ko) | 2022-09-08 | 2025-04-01 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | Kif18a 억제제 화합물, 약제학적 조성물 및 이의 제조 방법과 적용 |
| CN117683017A (zh) | 2022-09-09 | 2024-03-12 | 先声再明医药有限公司 | 芳酰胺类化合物、其组合物及用途 |
| WO2024051812A1 (zh) | 2022-09-09 | 2024-03-14 | 先声再明医药有限公司 | 酰胺类化合物、其组合物及用途 |
| CN119072473A (zh) | 2022-09-30 | 2024-12-03 | 长春金赛药业有限责任公司 | 稠环类kif18a抑制剂化合物、药物组合物及其制备方法和应用 |
| WO2024067465A1 (zh) | 2022-09-30 | 2024-04-04 | 山东轩竹医药科技有限公司 | Kif18a抑制剂 |
| CN119894878A (zh) | 2022-10-13 | 2025-04-25 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| WO2024083137A1 (zh) | 2022-10-19 | 2024-04-25 | 海南先声再明医药股份有限公司 | 稠合杂芳烃类化合物、其组合物及用途 |
| CN117917405A (zh) | 2022-10-21 | 2024-04-23 | 杭州邦顺制药有限公司 | Kif18a蛋白抑制剂 |
| JP2025538601A (ja) | 2022-11-24 | 2025-11-28 | インベンティスバイオ カンパニー リミテッド | 複素環化合物、その製造方法および用途 |
| CN115594664B (zh) | 2022-11-25 | 2023-02-24 | 英矽智能科技(上海)有限公司 | 一类螺环衍生物作为kif18a抑制剂 |
| CN120202002A (zh) | 2022-11-30 | 2025-06-24 | 微境生物医药科技(上海)有限公司 | 一种用于癌症治疗的药物组合物 |
| WO2024114787A1 (zh) | 2022-12-02 | 2024-06-06 | 深圳众格生物科技有限公司 | 酰胺或脲类化合物 |
| WO2024125488A1 (zh) | 2022-12-14 | 2024-06-20 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物、其制备方法和其在医药上的应用 |
| WO2024125626A1 (en) | 2022-12-16 | 2024-06-20 | Nuphase Therapeutics (Hangzhou) Limited., Co. | Nitrogenous compound, pharmaceutical composition and use thereof |
| IL321326A (en) | 2022-12-21 | 2025-08-01 | Amgen Inc | Cancer therapies using PRMT5 inhibitors collaborate with MTA |
| EP4642777A1 (en) | 2022-12-28 | 2025-11-05 | Insilico Medicine IP Limited | Inhibitors of kif18a and uses thereof |
| CN120569373A (zh) | 2023-01-05 | 2025-08-29 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和医药上的用途 |
| CN120418237A (zh) | 2023-01-09 | 2025-08-01 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| KR20250133439A (ko) | 2023-01-20 | 2025-09-05 | 인실리코 메디신 아이피 리미티드 | Kif18a의 억제제 및 그의 용도 |
| CN116199636A (zh) | 2023-02-21 | 2023-06-02 | 杭州医学院 | 靶向肿瘤免疫激酶的2,4-二取代嘧啶衍生物、制备方法及其应用 |
| TW202438053A (zh) | 2023-02-23 | 2024-10-01 | 美商佛拉斯托醫療公司 | Ｋｉｆ１８ａ吲哚啉抑制劑之固體調配物及多晶形式 |
| WO2024217348A1 (zh) | 2023-04-18 | 2024-10-24 | 南京同诺康医药科技有限公司 | Kif18a抑制剂及其制备方法和用途 |
| CN116535400B (zh) | 2023-04-26 | 2024-08-16 | 上海湃隆生物科技有限公司 | 氮杂螺环化合物及其应用 |
| CN121100117A (zh) | 2023-05-16 | 2025-12-09 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物、其制备方法和其在医药上的应用 |
| WO2024244972A1 (zh) | 2023-05-30 | 2024-12-05 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| WO2024259146A1 (en) | 2023-06-14 | 2024-12-19 | Volastra Therapeutics, Inc. | Method of treating cancer with indoline inhibitors of kif18a |
| WO2025007055A1 (en) | 2023-06-29 | 2025-01-02 | Volastra Therapeutics, Inc. | Aryl indol-3-yl ketone and aryl indazol-3-yl ketone inhibitors of kif18a |
-
2023
- 2023-08-18 PE PE2025000401A patent/PE20251601A1/es unknown
- 2023-08-18 TW TW112131231A patent/TW202416973A/zh unknown
- 2023-08-18 CR CR20250087A patent/CR20250087A/es unknown
- 2023-08-18 CA CA3264917A patent/CA3264917A1/en active Pending
- 2023-08-18 AU AU2023324826A patent/AU2023324826A1/en active Pending
- 2023-08-18 CN CN202380068844.7A patent/CN120187733A/zh active Pending
- 2023-08-18 KR KR1020257008820A patent/KR20250078442A/ko active Pending
- 2023-08-18 EP EP23772003.2A patent/EP4572855A1/en active Pending
- 2023-08-18 WO PCT/US2023/030544 patent/WO2024039829A1/en not_active Ceased
- 2023-08-18 JP JP2025509109A patent/JP2025529821A/ja active Pending
-
2025
- 2025-01-14 US US19/020,085 patent/US12391709B2/en active Active
- 2025-02-17 MX MX2025001982A patent/MX2025001982A/es unknown
- 2025-02-17 CL CL2025000445A patent/CL2025000445A1/es unknown
- 2025-03-13 CO CONC2025/0003263A patent/CO2025003263A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20250087A (es) | 2025-07-11 |
| CN120187733A (zh) | 2025-06-20 |
| US12391709B2 (en) | 2025-08-19 |
| MX2025001982A (es) | 2025-04-02 |
| CO2025003263A2 (es) | 2025-06-06 |
| JP2025529821A (ja) | 2025-09-09 |
| AU2023324826A1 (en) | 2025-02-27 |
| KR20250078442A (ko) | 2025-06-02 |
| TW202416973A (zh) | 2024-05-01 |
| CA3264917A1 (en) | 2024-02-22 |
| EP4572855A1 (en) | 2025-06-25 |
| WO2024039829A1 (en) | 2024-02-22 |
| US20250197428A1 (en) | 2025-06-19 |
| CL2025000445A1 (es) | 2025-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20251601A1 (es) | Inhibidores de kif18a y usos de estos | |
| PE20240775A1 (es) | Compuestos antivirales | |
| CO2022002804A2 (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CL2020001871A1 (es) | Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco. | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PE20250123A1 (es) | Inhibidores de cdk2 | |
| PE20251291A1 (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| PE20240017A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer | |
| PE20250674A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| ECSP034904A (es) | Derivados de índole naftil sustituido como inhibidores del activador plasminogen del inhibidor tipo-1 (pai-1) | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| MX2021012105A (es) | Compuestos de pirrol. | |
| CL2021003139A1 (es) | Compuestos tricíclicos | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| AR115965A1 (es) | Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática | |
| PH12021550512A1 (en) | Imidazopyridinone compound | |
| AR121341A1 (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| AR123582A1 (es) | Triazinonas inhibidores de la producción de inflamasoma de nlrp3 | |
| CL2023001440A1 (es) | Nuevos derivados de indazol acetileno | |
| PE20251588A1 (es) | Agonistas de ahr | |
| AR109712A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa |